Aaron Fletcher

Aaron Fletcher, Ph.D. has more than 10 years experience in biotech/healthcare equity industry and manages a portfolio of eight startups: 410 Medical, Abilitech Medical, Actuate Therapeutics, Azitra, Cognition Therapeutics, Encore Vision, Lantern Pharma and Lung Therapeutics.

Dr. Fletcher founded and serves as CEO of Bios Research, a financial services firm that provides public equity research in the healthcare space tailored to institutional firms and large family offices. Dr. Fletcher holds a Ph.D. in Biochemistry from Colorado State University, and serves as a professor at Dallas Baptist University where he teaches Biochemistry, Bioethics, and Cell Biology.